A Phase 2/3, Multicenter, Randomized, Double-blind, Parallel Group Comparative Study to Evaluate the Efficacy and Safety of Once-monthly Oral Administration of NE-58095DR Tablet (25 mg or 37.5 mg) Versus Once-daily Oral Administration of NE-58095IR Tablet (2.5 mg) for the Treatment of Involutional Osteoporosis

Trial Profile

A Phase 2/3, Multicenter, Randomized, Double-blind, Parallel Group Comparative Study to Evaluate the Efficacy and Safety of Once-monthly Oral Administration of NE-58095DR Tablet (25 mg or 37.5 mg) Versus Once-daily Oral Administration of NE-58095IR Tablet (2.5 mg) for the Treatment of Involutional Osteoporosis

Completed
Phase of Trial: Phase II/III

Latest Information Update: 03 Mar 2017

At a glance

  • Drugs Risedronic acid (Primary)
  • Indications Male osteoporosis; Postmenopausal osteoporosis
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Ajinomoto Pharma; Takeda
  • Most Recent Events

    • 07 Feb 2017 Status changed from active, no longer recruiting to completed, according to ClinicalTrials.gov record.
    • 07 Feb 2017 Status changed from active, no longer recruiting to completed, according to ClinicalTrials.gov record.
    • 05 Mar 2014 New source identified and integrated ClinicalTrials.gov record (NCT02066376) (it is a duplicate record)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top